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Abstract 
 
Schizophrenia is a very common psychiatric disorder. However, its etiology and 
pathogenesis is still unknown. Current theory saying that neurotransmitter 
imbalance such as serotonin or dopamine only provides limited effectiveness in 
schizophrenia treatment by drugs changing serotonin and dopamine concentration. 
Despite of such treatment, majority of schizophrenia patients still have very poor 
prognosis. Thus, the neurotransmitter imbalance theory is not correct. Here, I 
propose that schizophrenia is actually a TH2 dominant autoimmune disorder. The 
candidate of autoantigen could be acetylcholine receptors of CNS. My theory can 
explain the positive as well as negative symptoms of schizophrenia. By microarray 
analysis of PBMCS, one-tenth of the total 519 significantly expressed genes are 
immune-related genes. Among them, TH2 related genes are significantly 
up-regulated including IL-4, histidine decarboxylase, aldehyde dehydrogenase, CCR9, 
IgE Fc receptor, GATA2, serotonin receptor, phospholipase A2, and prostaglandin D2 
synthase. Besides, TH1 and TH17 related genes are down-regulated including CXCL5, 
cathepsin C, and neutrophil related S100 binding proteins. The new theory sheds a 
light to better control this detrimental illness. Anti-inflammatory agents could be 
used to manage schizophrenia in the near future. 
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Introduction 
 
Schizophrenia is the most detrimental psychiatric disease. Its incidence and 
prevalence are higher in developed countries. Although this illness has a very high 
impact on global health, its etiology or pathogenesis is still not known. Currently, the 
most popular theory for schizophrenia etiology is neurotransmitter imbalance theory. 
The theory says that the imbalance of brain neurotransmitters such as dopamine and 
serotonin cause the symptoms and signs of schizophrenia. According to this theory, 
many drugs developed to modify CNS neurotransmitter concentrations to try to 
control schizophrenia. Even the symptoms of hallucination and delusion are 
improved a little bit by these agents, the long term prognosis of schizophrenia is still 
very poor. Thus, the neurotransmitter imbalance theory may not correct. If we don’t 
know the real etiology or pathophysiology of this disease, we cannot use the correct 
management strategy to control schizophrenia. Here, I use microarray analysis and 
literature reviews to demonstrate that schizophrenia is actually a TH2 dominant 
autoimmune disease. Acetylcholine receptor of CNS should be the most likely 
candidate for the autoantigen.  
 
Material and Methods 
 
Blood samples 
 
Second hand data analysis was performed by using the GEO sample set. In the San 
Diego sample set, participants were recruited from University of California, San Diego 
(UCSD) Psychopharmacology Research Initiatives Center for Excellence (PRICE). 
Inclusion criteria are: 1. Age between 18 and 55 years-old 2.at least eighth-grade 
education 3. English is their first language 4. No mental retardation. Exclusion criteria 
are: 1. Substance abuse or dependence 2. Neurological problems such as stroke or 
meningitis 3. Systemic medical illness such as heart disease or diabetes 4. History of 
head injury with documented loss of consciousness lasting longer than 10 minutes 5. 
Pregnancy 6. Physical disabilities.  
 
Whole blood samples (10ml) were collected in the morning after subjects fasted 
overnight with EDTA-coated collection tubes. Then, peripheral blood mononuclear 
cells (PBMC) were acquired from LeukoLOCK filter. Eluted mRNA samples from 
PBMCs were then stored at -20⁰C until transferred to the GeneChip Microarray Core 
(San Diego, CA) for microarray hybridization. Final, thirteen schizophrenia samples 
were hybridized to GeneChip Human Exon 1.0 ST Arrays (Affymetrix, Inc., Santa Clara, 
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CA).  
 
Microarray analysis 
 
The above microarray hybridization raw data (CEL files) have been uploaded onto 
GEO (GSE12288). I download these data set and redo the microarray expression 
significance analysis by using Genespring software. Unpaired student T-test with 
unequal variance and non-adjusted false discovery rate were used to analyze the 
data set in Schizophrenic patients’ blood samples compared to those of healthy 
control.  
 
Q-PT-PCR verification 
 
Professor Ian P. Everall et al. did quantitative reverse-transcriptase polymerase chain 
reaction (QRTPCR) verification for the exon array of the San Diego sample set. 
Aliquots of each mRNA sample were reverse transcribed to single stranded cDNA 
using SuperScript III First Strand cDNA Synthesis Kit (Invitrogen Corporation, Carlsbad, 
CA). Then, 50 ng of cDNA was used as the template in 20ul TaqMan reactions using 
ABI universal Master Mix primers and probes designed by Applied Biosystems (Foster 
City, CA). Gene specific standard curves for ARF1 (Assay ID Hs00796826_s1), BAT1 
(Assay ID Hs00366447_m1), and GDI2 (Assay ID Hs00357525_m1) were generated. 
The QRTPCR results of the selected three genes confirmed the microarray analysis of 
this experiment. Thus, the microarray procedure is validated.  
 
Results 
 
Global gene expression pattern in schizophrenia blood samples 
 
By Genespring analysis, we found 519 significant gene change (both up-regulation 
and down-regulation). Among the 519 genelist, 50 genes are immune-related. It 
suggests that host immune response plays an important role in the etiology or 
pathophysiology of schizophrenia. Thus, about one-tenth of all the significantly 
expressed genes are immune-related. Immune response plays an important role in 
schizophrenia. 
 
Special expressed genes in schizophrenia compared to previous association studies 
 
I compare the genelist from the microarray analysis result to previous association 
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studies. I find out that several schizophrenia-related genes are expressed in this 
genelist. These genes include serotonin receptor and TCF4. Thus, my analysis is 
consistent with previous association studies. (Table 1) 
 
Immune-related gene up-regulation in leukocytes of schizophrenia patients 
 
Among the 519 up-regulated or down-regulated genes in peripheral blood of 
schizophrenic patients, about one-tenth genes are immune-related. This means that 
host immune response are activated during the happening of schizophrenia. Thus, 
host immunological pathway is highly associated with the attack of schizophrenia. 
This result supports that schizophrenia is actually an autoimmune disorder. (Table 2) 
 
Th2 immunological pathway up-regulation in peripheral blood of schizophrenia 
patients 
 
According to my microarray analysis, many TH2 immune response related 
genes are up-regulated in schizophrenia. Among this dataset, the key TH2 
driven cytokine IL-4 is significantly up-regulated during the attack of 
schizophrenia. Thus, we can infer that TH2 autoimmunity is activated in 
schizophrenia. Besides, histidine decaboxylase, the key enzyme for 
production of histamine, is highly up-regulated in peripheral blood of 
schizophrenia. Histamine is a key mediator of TH2 immunological pathway. 
With the up-regulation of IL-4 and histamine, TH2 dominant immune 
response should happen in schizophrenic patients. (Table3) Besides, many 
TH2 related genes are up-regulated in schizophrenic patients including 
carboxypeptidase A3, CXCL5, S100 binding protein A12, CCR9, IgE Fc 
receptor, reticulocalbin 3, GATA2, integrin alpha 1, interleukin 4, secretary 
leukocyte peptidase inhibitor, phospholipase A2, cathepsin C, glutathione 
peroxidase 1, retinol binding protein 2, and prostaglandin D2 synthase.  
 
Discussion 
 
Schizophrenia is very common and detrimental psychiatric disorder. Despite of its 
importance, the etiology and pathophysiology of schizophrenia is not clearly known. 
Currently, the most accepted theory for schizophrenia pathogenesis is 
neurotransmitter imbalance theory. In this theory, imbalance of dopamine, serotonin, 
and glutamate can account for the happening of schizophrenia. Thus, current 
medications for schizophrenic patients are drugs to modify the brain concentration 
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of these neurotransmitters. Despite of this kind of treatment, the prognosis of 
schizophrenia is still very poor. Majority of schizophrenic patients are severely 
disabled in their lifetime. Many of them commit suicide because they cannot tolerate 
the disease progression. The ineffectiveness of neurotransmitter modification 
suggests that neurotransmitter imbalance is not the actual cause of schizophrenia.  
 
Among these neurotransmitters, dopamine hypothesis is most widely accepted. 
Several researchers suggested that dopamine system in the mesolimbic pathway may 
contribute the positive symptoms of schizophrenia such as delusion or hallucination. 
The excessive dopamine in brain causes the attack of schizophrenia. Certain studies 
found out that amphetamine and cocaine, two illegal drugs which can lead to 
schizophrenia symptoms, can increase the brain concentration of dopamine.(Ito 2004; 
Fox, Esbenshade et al. 2005) Thus, it is the reason of amphetamine psychosis and 
cocaine psychosis. However, these are several defects of the dopamine hypothesis. 
Dopamine is a neurotransmitter which is related to motivation. The excessive 
dopamine may explain the positive symptoms such as hallucination and delusion. 
Actually, the excessiveness of dopamine in brain usually causes euphoria, alertness, 
and over-confidence; these symptoms are more reminiscent of mania than 
schizophrenia. However, the more detrimental negative symptoms such as avolition 
(lack of motivation) cannot be explained by the excessive dopamine hypothesis. 
Actually, it is the opposite. PET scan was used to study the brain functional dopamine 
receptors.(Seok Jeong, Kwon et al. 2005) When schizophrenia patients have 90% 
block of dopamine D2 receptors by certain antipsychotic agents, these is little 
reduction of the psychoses behavior. Furthermore, although dopamine inhibiting 
medications modify dopamine levels within minutes, the positive symptoms of 
schizophrenia only subside at least several days or even weeks. In addition, the main 
target of new generation of antipsychotic agents such as clozapine and quetiapine is 
not dopamine receptors. They bind and unbind dopamine receptors rapidly in brain. 
Besides, other psychosis inducing agents such as phencyclidine and ketamine don’t 
have any effect on the brain concentration of dopamine.(Wang, McInnis et al. 2001) 
Besides the functional anomalies in schizophrenia, there are also anatomical 
anomalies in schizophrenia such as ventricle enlargement and brain atrophy.(Roberts 
1991) Dopamine imbalance cannot explain the pathopsysiology of schizophrenia. 
However, it is worth noting that dopamine can be secreted by immune cells such as T 
lymphocytes. Dopamine is a strong immune-mediator suppressing prolactin. 
Prolactin is usually secreted in late pregnancy to activate Treg cells via STAT5 to 
suppress maternal immunity.(Gaufo and Diamond 1996; Cosentino, Fietta et al. 2007) 
Thus, dopamine can suppress the function of regulatory T cells to enhance 
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lymphocyte immunity. This also links the dopamine’s work and autoimmunity in 
schizophrenia. 
 
Serotonin excessiveness is more likely to be related to the positive symptoms of 
schizophrenia. LSD, an illegal drug which can modulate brain serotonin concentration, 
can induce visual or auditory hallucination.(Rivero, Sanjuan et al. 2010) In addition, 
many new generation antipsychotic agents are serotonin modifiers. It is possible that 
the hallucination induced by serotonin induce the subsequent delusion in 
schizophrenia. However, the excessive serotonin still cannot explain the negative 
symptoms of schizophrenia such as blunt emotion and avolition. It cannot explain the 
anatomical anomalies such as brain atrophy and ventricle enlargement in 
schizophrenic patients, either.(Seok Jeong, Kwon et al. 2005) Neurotransmitter 
imbalance may only explain the functional anomalies but not the anatomical 
anomalies in schizophrenic patients. Many new generation anti-psychotic agents are 
5HT1A antagonists. That suggest that serotonin plays an important role in positive 
symptoms of schizophrenia such as hallucination and delusion.  
 
Many risk factors have been linked to the incidence of schizophrenia such as genetic 
inheritance, infection, environmental factors such as drug usage. If we want to link all 
the risk factors for schizophrenia, autoimmunity is the most likely etiology of 
schizophrenia. If schizophrenia is a TH2 dominant autoimmune disorder, it can 
explain many phenomenon seen in schizophrenic patients. The incidence of 
schizophrenia is higher in the developed countries and urban area. Current theory 
thinks the stress in industrial nations may aggravate schizophrenia. However, it could 
be actually the environmental plasticizer concentration is higher in these developed 
nations. These plasticizers such as DEHP are strong TH2 driving agents. Thus, TH2 
related allergic and autoimmune diseases are rising in industrial nations. Many 
association studies show that acetylcholine receptors such as nicotinic receptors or 
muscarinic receptors are related to the schizophrenia.(Freedman, Leonard et al. 2001) 
Actually, these acetylcholine receptors in brain neurons can be the autoantigens for 
this TH2 autoimmune disease.(Henneberg, Horter et al. 1994; Yang, Chengappa et al. 
1994) Thus, these TH2 autoimmune cells can attack CNS neurons by recognizing 
these cortical acetylcholine receptors. Finally, brain atrophy and ventricle 
enlargement happen after immune destruction. Only autoimmune mechanism can 
explain the negative symptoms of schizophrenia. Alpha 7 CNS nicotinic acetylcholine 
receptor is a widely accepted gene linking to schizophrenia. In postmortem studies, 
the acetylcholine receptor numbers are severely decreased in schizophrenia 
patients.(Gault, Hopkins et al. 2003) Autoantibody for alpha 7 CNS nicotinic 
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acetylcholine receptor is also found in schizophrenia patients.(Chandley, Miller et al. 
2009) Tobacco usage is highly associated with the schizophrenia.(Dalack, Healy et al. 
1998) It is likely the nicotinic acetylcholine receptors are targeted and damaged by 
TH2 autoimmune cells. Thus, schizophrenic patients need to smoke to stimulate their 
nicotinic receptors to maintain brain function. It is worth noting that HSV and CMV 
antibodies are often found in serum of schizophrenia patients.(Albrecht, Torrey et al. 
1980; Yolken and Torrey 1995) Thus, molecular mimicry between viral antigen and 
brain antigen may play an important role in the pathogenesis of schizophrenia. In a 
JCI paper, there is cross reactivity between acetylcholine receptor and HSV viral 
antigen.(Schwimmbeck, Dyrberg et al. 1989) HSV usually causes latency infection of 
neurons. In addition, HSV encephalitis usually causes symptoms such as hallucination 
and behavior change. Thus, HSV or CMV could be important causing factor of 
schizophrenia. Possible dietary antigen is also investigated in schizophrenia 
patients.(Severance, Lin et al. 2011) An animal model of schizophrenia is DISC1 
genetic modified mice.(Hikida, Jaaro-Peled et al. 2007; Mathew, Law et al. 2007) 
DISC1 and neuregulin 1 are both related to nicotinic acetylcholine receptor. This also 
matches my hypothesis.  
 
Serotonin is a key mediator in TH2 immunological pathway. The function of serotonin 
in TH2 immune response is to induce diarrhea in GI tract and to induce 
bronchospasm to expel the intestinal or bronchopulmonary parasites. Serotonin can 
also activate T lymphocytes.(Leon-Ponte, Ahern et al. 2007) However, serotonin is 
also a neurotransmitter. When the TH2 autoimmune cells reach the CNS, they can 
release a lot of serotonin to brain cortex to cause hallucination and subsequent 
delusion.(Rivero, Sanjuan et al. 2010) Basophils, mast cells, and TH2 CD4 T cells can 
also release serotonin.(Abramovitz, Altboum et al. 1991) Thus, this TH2 
autoimmunity hypothesis can also satisfactorily explain the positive symptoms of 
schizophrenia.  
 
Many schizophrenia patients have the sensation of pseudoparasites (delusional 
parasitosis). They think they have parasite moving in their body such as under the 
skin. If schizophrenia is a TH2 dominant autoimmune disorder, it can explain this 
common phenomenon in schizophrenia. TH2 immunological pathway is the host 
immunity against helminthes parasites. In TH2 immune response, histamine is 
released by mast cells or basophils to cause the itchiness sensation. Thus, 
schizophrenic patients will think they are infected by parasites. This kind of “delusion” 
suggests that schizophrenia is a TH2 autoimmunity. 
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Another common symptom in schizophrenia is that patients always feel thirsty and 
drink a lot of water. This can be explained by histamine. In CNS, histaminergic 
neurons secreting histamine control the desire of thirst.(Ito 2004) Thus, if there are 
too many histamines in brain, patients will feel extremely thirsty. Histamine is a key 
effector molecule in TH2 immunity. This phenomenon also suggests that 
schizophrenia is a TH2 dominant autoimmune illness.  
 
First, schizophrenia patients need to have specific type of HLA to recognize a brain 
autoantigen such as alpha 7 nicotinic receptor. In addition, accessory molecules play 
the function like toll-like receptor should be present to trigger TH2 immunological 
pathway. CNS histaminergic neurons secreting histamine play the key role here. 
Many schizophrenia inducing agents such as PCP, amphetamine, or cocaine can 
induce the release of histamine in CNS.(Prell, Green et al. 1995) Then, histamine can 
favor this autoimmune to the TH2 immunological pathway. Antihistamine treatment 
of schizophrenia has been studied and it is functional.(Stevens 1962; Fox, 
Esbenshade et al. 2005) Histamine receptor allele polymorphism is also related to 
schizophrenia.(Orange, Heath et al. 1996) As long as the presence of the autoantigen 
and accessory molecule, the TH2 autoimmunity will persist. Serotonin released from 
TH2 CD4 T cells, basophils, and mast cells causes hallucination and subsequent 
delusion. Finally, these TH2 autoantibodies and autoimmune T cells can destroy CNS 
neurons to cause brain atrophy with ventricle enlargement. Due to the CNS neuron 
death, the negative symptoms such as avolition, poverty of thought, social withdraw, 
and speech/behavior disorganization will appear in schizophrenic patients. This TH2 
autoimmune hypothesis can well explain the pathophysiology of schizophrenia.  
 
Multiple sclerosis is also a TH2 autoimmune disorder. There are some overlaps 
between multiple sclerosis and schizophrenia.(Stevens 1988) Histaminergic neurons 
also play important roles in trigger TH2 autoimmunity of multiple sclerosis. However, 
the major autoantigen in multiple sclerosis is myelin protein. Thus, the major target 
of autoimmune cells or antibodies in multiple sclerosis is myelin sheath. Neurons are 
seldom destroyed. Thus, there are infrequent negative symptoms such as avolition or 
social withdraw in multiple sclerosis. In addition, myelin sheath is more dominant in 
optic nerves or spinal cord. Thus, optic nerves or spinal cord are first affected in 
multiple sclerosis. However, in the final stage of multiple sclerosis, TH2 autoimmune 
cells can also enter CNS and release serotonin to cause symptom such as 
hallucination.  
 
Myasthenia gravis is also an autoimmune disease. The main autoantigen of 
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myasthenia gravis is acetylcholine receptors. In my theory, autoantigens in 
schizophrenia are also nicotinic or muscarinic acetylcholine receptors. Several papers 
found that anti-cholinergic receptor antibodies are found in schizophrenia 
patients.(Mukherjee, Mahadik et al. 1994; Borda, Perez Rivera et al. 2002; Chandley, 
Miller et al. 2009) However, the specific type of autoantigen in myasthenia gravis is 
on the neuromuscular junction. On the contrary, the specific type of acetylcholine 
receptor in schizophrenia is located in CNS. In addition, myasthenia gravis is a 
TH9(THαβ) dominant autoimmune disorder not like the TH2 dominance in 
schizophrenia. Thus, schizophrenia and myasthenia gravis are different diseases. 
Because one is TH2 and the other is THαβ, it is very rare that the two diseases appear 
in one patient concurrently. This is the mutual antagonism suggested by several 
papers. It is worth noting that thymusmyoid cells bearing AchR are the sources of 
autoantigens in myasthenia gravis. Thymoma or thymus hyperplasia is usually found 
in myasthenia gravis. In a PNAS paper, autoantibodies against thymocytes are also 
noted in serum of schizophrenia patients.(Luria and Domashneva 1974) Thus, the 
autoantigen of schizophrenia might also be AchR.   
 
Witebsky’s postulates are the standard criteria to decide if a disorder is an 
autoimmune disease. There are three requirements in Witebsky’s postulates: 1. 
Direct evidence from transfer of pathogenic antibody or T cells 2. Indirect evidence 
based on reproduction of the autoimmune disease in experimental animal 3. 
Circumstantial evidence from clinical clues. Actually, schizophrenia fulfils the three 
criteria. Inflammatory-related genes, β2 microglobulin, CTLA4 are up-regulated in 
schizophrenia.(Saetre, Emilsson et al. 2007; Teixeira, Reis et al. 2008; Chittiprol, 
Venkatasubramanian et al. 2009) In the first criteria, increased B cells, IL-4 T cells, 
eosinophils, and basophils are seen in schizophrenic patients.(Pfeiffer, Iliev et al. 
1971; Leonard 2005; Drexhage, Hoogenboezem et al. 2011) TH2 cytokine such as 
IL-13 level is decreased after effective anti-psychiatric medication in schizophrenia 
patients.(Pae, Yoon et al. 2006) Anti-brain antibodies, especially IgE antibodies, are 
found in serum and CSF of schizophrenia patients.(Bock, Weeke et al. 1970; 
Ramchand, Wei et al. 1994; Yang, Chengappa et al. 1994) Elevated eosinophil cationic 
protein and eosinophil chemoattractant eotaxin are also noted in 
schizophrenia.(Hallgren, Venge et al. 1982; Teixeira, Reis et al. 2008) This suggests 
that schizophrenia is a TH2 dominant immune disease.(Muller, Riedel et al. 2000) In 
the second criteria, anti-brain antibody transfer into animals such as mice can induce 
the EEG and behavior change like schizophrenia. In the third criteria, there is a very 
strong of HLA association with schizophrenia inheritance. This is reported in Nature 
magazine.(Shi, Levinson et al. 2009; Stefansson, Ophoff et al. 2009) Specific HLA 
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haplotypes are also linked to schizophrenia incidence. Several TH2 autoimmune 
diseases such as asthma are linked to the coincidence of schizophrenia. However, 
TH17 autoimmune diseases such as rheumatoid arthritis are inversely correlated to 
the incidence of schizophrenia.(Jones, Mowry et al. 2005) The key anti-TH17 IL-1 
receptor antagonist is also up-regulated in schizophrenia.(Akiyama 1999) In addition, 
there is no association with schizophrenia and key TH17 cytokines: IL-1 and 
TNFα.(Chowdari, Xu et al. 2001; Handoko, Nancarrow et al. 2003; Saiz, Garcia-Portilla 
et al. 2006) Although there are several reports about up-regulation of IL-6 in 
schizophrenia, IL-6 is not a solely TH17 cytokine. It is a general cytokine to induce 
acute phase response in liver during various pathogen infections. Thus, TH17 
autoimmunity for schizophrenia is unlikely. Retinoic acid, which can prevent 
eosinophil apoptosis, is also reported to be related to schizophrenia.(Goodman 1995; 
Goodman 1998; Ueki, Mahemuti et al. 2008) Retinoic acid responsive transcription 
factor-RORC is also related to TH2 immunity activation(Putheti, Awasthi et al. 2010). 
Several pathogens are like to the occurrence of schizophrenia. Among these 
pathogens, toxoplasma gondii is the strongest link. Toxoplasma parasite mainly 
induces TH2 dominant immune response. Toxoplasma infection can favor a TH2 
biased host environment. Thus, it also suggests schizophrenia is a TH2 dominant 
autoimmune disorder. In the Northern Hemisphere, persons with schizophrenia are 
more often born in the months from January to April. In the Southern Hemisphere, 
persons with schizophrenia are more often born in the months from July to 
September. This could be due to the lowest maternal vitamin D level in these months 
during pregnancy.(Kinney, Teixeira et al. 2009) Vitamin D is a strong TH1 activator and 
effector. Thus, vitamin D will suppress TH2 immunity. This can explain why birth 
season affects schizophrenia incidence. The TH1 effector cells are down-regulated in 
schizophrenia.(Freudenreich, Brockman et al. 2010) THαβ(TH9) immunity is also 
unlikely because of the down-regulation of NK cells and lack of association with IL-10 
in schizophrenia.(Abdeljaber, Nair et al. 1994; Sperner-Unterweger, Whitworth et al. 
1999; Jun, Pae et al. 2003) The onset of male schizophrenia is from 10 to 25 years old, 
and the onset of female schizophrenia is from 25 to 35 years old. Schizophrenia will 
occur after the Treg reduction with the atrophy of thymus during about 10 years old. 
The later onset of female schizophrenia can be due to the anti-inflammatory effect of 
estrogen. Estrogen action delays the onset of schizophrenia in female. DiGeorge 
syndrome is manifested by thymus atrophy. Thus, Treg production is severely lacking 
in DiGeorge syndrome. The occurrence of schizophrenia is 100 times higher in 
DiGeorge syndrome. Schizophrenia is related to lower Treg and IL-2 levels.(Achiron, 
Noy et al. 1994) IL-2 is a cytokine to stimulate regulatory T cells. This implies that 
schizophrenia is an autoimmune disease. In several clinical studies, 
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anti-inflammatory drugs such as aspirin and NSAIDs can slow down schizophrenia 
progression(Akhondzadeh, Tabatabaee et al. 2007; Laan, Grobbee et al. 2010). It also 
suggests that schizophrenia is an autoimmune disorder.  
 
In addition, many cytokine gene polymorphism is related to the incidence of 
schizophrenia especially IL-4 and IL-6.(Mittleman, Castellanos et al. 1997) IL-6 is 
found to be up-regulated in CSF and serum of schizophrenia patients.(Akiyama 1999) 
In addition, IL-2 is down-regulated in CSF and serum of schizophrenia. IL-6 and STAT3 
are also important mediators in TH2 immunity. IL-2 is the main effector of T 
regulatory cells. Thus, up-regulation of TH2 helper cells and down-regulation of Treg 
cells can contribute to the occurrence of schizophrenia. Humeral immunity such as 
complement activation is also reported in schizophrenic patients.(Maes, Delange et 
al. 1997) Humeral immunity is the manifestation of TH2 immunological pathway.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
12
.6
97
8.
1 
: P
os
te
d 
11
 M
ar
 2
01
2
Table 1. Reported schizophrenic-related gene in PBMCs of schizophrenia 
Symbol p-value Arrow Fold Gene Description 
Schizophrenia 
   HTR1A 0.028  up 1.27  5-hydroxytryptamine (serotonin) receptor 1A 
TCF4 0.023  down 1.21  transcription factor 4 
PCDHB1 0.004  up 1.12  protocadherin beta 1 
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Table 2. Immune-related gene up-regulation in PBMCs of schizophrenic patients 
Symbol p-value Arrow Fold Gene Description 
Immune 
    PVRL2 0.036  up 1.50  poliovirus receptor-related 2 (herpesvirus entry) 
GPR162 0.022  up 1.41  G protein-coupled receptor 162 
CPN1 0.007  up 1.38  carboxypeptidase N, polypeptide 1 
NDUFA4 0.023  down 1.35  NADH dehydrogenase 1 alpha subcomplex, 4 
Septin7 0.023  down 1.33  septin 7 
TSPAN18 0.020  up 1.30  tetraspanin 18 
CLEC1B 0.029  up 1.28  C-type lectin domain family 1, member B 
NKX3-1 0.049  up 1.28  NK3 homeobox 1 
LY96 0.031  down 1.27  lymphocyte antigen 96 
SH3BP5 0.002  down 1.26  SH3-domain binding protein 5 (BTK-associated) 
PLEKHB2 0.016  down 1.26  pleckstrin homology domain containing, B 2 
TIPRL 0.015  down 1.25  TIP41, TOR signaling pathway regulator-like  
RTN1 0.049  up 1.24  reticulon 1 
FTK3 0.028  up 1.22  fms-related tyrosine kinase 3 
RTN4RL1 0.018  up 1.22  reticulon 4 receptor-like 1 
ITGB8 0.012  up 1.22  integrin, beta 8 
TOM1L2 0.035  up 1.21  target of myb1-like 2 (chicken) 
NLRP1 0.045  up 1.21  NLR family, pyrin domain containing 1 
TMIGD2 0.044  up 1.20  transmembrane and immunoglobulin domain 2 
LY6G6C 0.005  up 1.20  lymphocyte antigen 6 complex, locus G6C 
HCG27 0.017  up 1.20  HLA complex group 27 
S100A7A 0.014  up 1.20  S100 calcium binding protein A7A 
NCR2 0.027  up 1.19  natural cytotoxicity triggering receptor 2 
CLEC11A 0.031  up 1.16  C-type lectin domain family 11, member A 
LTK 0.025  up 1.15  leukocyte receptor tyrosine kinase 
IVNS1ABP 0.036  down 1.14  influenza virus NS1A binding protein 
RORC 0.031  up 1.14  RAR-related orphan receptor C 
ITGA5 0.049  up 1.13  integrin, alpha 5  
CPN2 0.042  up 1.13  carboxypeptidase N, polypeptide 2 
IGSF11 0.022  up 1.10  immunoglobulin superfamily, member 11 
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Table 3. TH2 related gene up-regulation in PBMCs of schizophrenic patients 
Symbol p-value Arrow Fold Gene Description 
TH2 
    HDC 0.001  up 1.57  histidine decarboxylase 
ALDH1A1 0.002  up 1.52  aldehyde dehydrogenase 1 family, member A1 
CPA3 0.044  up 1.36  carboxypeptidase A3 (mast cell) 
CXCL5 0.049  down 1.35  chemokine (C-X-C motif) ligand 5 
S100A12 0.030  down 1.30  S100 calcium binding protein A12 
TPST1 0.050  up 1.33  tyrosylprotein sulfotransferase 1 
CCR9 0.020  up 1.30  chemokine (C-C motif) receptor 9 
FCER1A 0.005  up 1.30  Fc fragment of IgE, high affinity I, receptor alpha  
RCN3 0.014  up 1.29  reticulocalbin 3, EF-hand calcium binding domain 
GATA2 0.005  up 1.27  GATA binding protein 2 
HTR1A 0.028  up 1.27  5-hydroxytryptamine (serotonin) receptor 1A 
ITGA1 0.014  down 1.23  integrin, alpha 1 | pelota homolog  
IFNI16 0.024  down 1.22  interferon, gamma-inducible protein 16 
IL4 0.011  up 1.20  interleukin 4 
SLPI 0.013  down 1.75  secretory leukocyte peptidase inhibitor 
PLA2 0.042  up 1.22  phospholipase A2, group IIF 
CTSC 0.014  down 1.20  cathepsin C 
GPX1 0.008  up 1.16  glutathione peroxidase 1 
RBP2 0.007  up 1.16  retinol binding protein 2, cellular 
IL22RA1 0.007  up 1.12  interleukin 22 receptor, alpha 1 
PGDS 0.025  up 1.11  prostaglandin D2 synthase, hematopoietic 
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